Skip to main content
. 2018 Apr 6;9:146. doi: 10.3389/fendo.2018.00146

Figure 5.

Figure 5

SSTR2 reintroduction does not sensitize human neuroendocrine tumor (NET) cells to octreotide treatment. (A) Human SSTR2-transfected NET cell lines BON and QGP-1 were treated with increasing concentrations of octreotide (0.1 pM–10 µM), incubated for 96 h and analyzed for viability (metabolic activity). (B) For comparison, wild-type and ratSSTR2-GFP-transfected RIN-1038 cells were analyzed in the same way. Data represent mean ± SEM (n = 2–4).